CCM
RYTM icon

CAAS Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

CAAS Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84,044
Closed -$1.65M – 1090
2021
Q2 		$1.65M Sell
84,044
-533,551
-86% -$11.1M 0.03% 437
2021
Q1 		$13.1M Buy
+617,595
New +$17.9M 0.14% 173

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's RYTM Position: Q3 2021 in Review

CAAS Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2021, closing a stake of 84,044 shares — an estimated $1.65M sold.

CAAS Capital Management first reported a position in RYTM in Q1 2021 and held it in 2 quarters. The position peaked at $13.1M in Q1 2021. 97 funds tracked by Wall St. Rank hold RYTM as of Q3 2021.

  • CAAS Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 84,044 Rhythm Pharmaceuticals shares in Q3 2021, an estimated $1.65M.
  • CAAS Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • CAAS Capital Management's Rhythm Pharmaceuticals position peaked at $13.1M in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.